ATLANTA, Aug. 30, 2019 /PRNewswire/ -- MiRus announces successful spine surgeries at several centers across the country using the MoRe® superalloy. MiRus had received FDA 510(k) clearance for the MoRe® based Europa™ Pedicle Screw System earlier this year.

MoRe®, a proprietary molybdenum rhenium superalloy for medical implants, provides an unprecedented combination of strength, ductility, durability, and biological safety. The MoRe® superalloy allows for the design of a new generation of smaller, stronger, more durable, and bio-friendly pedicle screw implants that should result in less soft tissue disruption, quicker recovery and better outcomes for patients.

"The EUROPA pedicle screw system with the 4.5mm MoRe rod has provided a valuable addition to my armamentarium" noted Matthew McGirt MD, Neurosurgeon at Carolina Neurosurgery & Spine Associates in North Carolina. "The 4.5mm MoRe rod has allowed me to do a pedicle screw fixation with an incredibly small profile providing many benefits such as increased surface area for bone grafting, ease of interbody placement, and the ability to work on nerves around the rod and pedicle screw system. In addition, the malleability of the 4.5 MoRe rod despite its strength and durability, has been a tremendous advantage in long constructs."

Jason Cormier MD, Neurosurgeon at Acadiana Neurosurgery in Louisiana stated, "I have had a primarily MIS practice for years and have done thousands of cases with 20 different MIS systems, I have found the Europa pedicle screw system along with the 4.5mm MoRe alloy rod to be exceptionally beneficial to my patients in terms of recovery. The very small pedicle tulips lead to less facet pain and soft tissue disruption and the strength and fatigue resistance of the MoRe rod allows for a better overall construct. I have found no other pedicle screw system that offers the comprehensive benefits of this system."

"This is a momentous event for patients, surgeons and for us," added Jay S. Yadav MD, CEO of MiRus "as we see patients benefitting from the years of basic science research conducted by our team."

MiRus is fortunate to be collaborating with an outstanding worldwide group of orthopaedic and neurosurgeons in developing transformative spine solutions. Application of the MoRe® superalloy is rapidly expanding into other applications such as foot and ankle, upper extremity, CMF and cardiovascular.

About MiRus, LLC. MiRus is a medical device company that has developed and is commercializing proprietary novel biomaterials, implants and software solutions for spine, orthopaedics and cardiovascular disease. We are addressing the demands of today's healthcare environment with an integrated platform of pre-operative planning and risk assessment tools, a breakthrough navigation and robotics system and post-operative monitoring and risk mitigation. Find more information about MiRus at www.mirusmed.com.

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

* MoRe® is a registered trademark of MiRus, LLC. Europa™ and MiRus™ are trademarks of MiRus, LLC.

Contact: Mahesh Krishnan VP, Sales and Marketing, MiRus mkrishnan@mirusmed.com 770-317-5564

View original content to download multimedia: http://www.prnewswire.com/news-releases/first-spine-surgeries-using-the-more-superalloy-300909762.html

SOURCE MiRus

Subscribe to Daily Headlines

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

For copyright information, check with the distributor of this item, PR Newswire.

Load comments